I'm LongbridgeAI, I can summarize articles.Bell Potter has reaffirmed a Buy rating on Vitrafy Life Sciences Ltd. (VFY) with a price target of A$3.00. Analyst Martyn Jacobs, who has an average return of -19.8% and a 16.39% success rate, covers the Healthcare sector. The analyst consensus for Vitrafy is a Moderate Buy, with a price target consensus of A$2.33.
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Vitrafy Life Sciences Ltd., with a price target of A$3.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Jacobs is an analyst with an average return of -19.8% and a 16.39% success rate. Jacobs covers the Healthcare sector, focusing on stocks such as Medical Developments International Limited, Oneview Healthcare Chess Depository Interests repr 1, and Sonic Healthcare Limited.
Vitrafy Life Sciences Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of A$2.33.